This article refers to:
Additional information
Funding
This work was supported by the National Center for Advancing Translational Sciences (UL1 TR002319).
The American Journal of Bioethics
Volume 20, 2020 - Issue 4
CASE COMMENTARIES
Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions
Kathryn M. PorterSeattle Children’s Hospital and Research Institute; Correspondence[email protected]
http://orcid.org/0000-0003-1930-9625View further author information
http://orcid.org/0000-0003-1930-9625View further author information, & ![Sample our Humanities journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5939/TOC-Subject-Sample-2021-Humanities.jpg"})
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
Source:
BMJ
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial
Source:
Elsevier BV
Linking provided by
